News
- Author:
- Neil Osterweil
Publish date: September 4, 2018
Survival outcomes were better for patients treated at centers caring for a mean of 20 patients per year compared with 5 or 10 per year.
News
- Author:
- Neil Osterweil
Publish date: August 31, 2018
Response rates and overall survival were better with dose-dense MVAC vs. gemcitabine and a platinum compound in muscle-invasive disease.
News
- Author:
- Neil Osterweil
Publish date: August 31, 2018
Despite failure to prove its hypothesis, a phase 2 trial suggested that nab-paclitaxel/gemcitabine may offer efficacy comparable to that of gemcita...
News
- Author:
- Neil Osterweil
Publish date: August 30, 2018
Despite a handful of durable remissions of non-Hodgkin lymphomas with the antibody-drug conjugate, thrombocytopenias canceled out the benefit.
News
- Author:
- Neil Osterweil
Publish date: August 16, 2018
CHICAGO – The agent blocks DNA transcription and induces double-strand breaks leading to apoptosis; results warrant further exploration, researcher...
News
- Author:
- Neil Osterweil
Publish date: August 16, 2018
Tumor morphology suggested the presence of a renal hemangioma but staining produced mixed signals, pathologists reported.
News
- Author:
- Neil Osterweil
Publish date: August 15, 2018
These rare tumors of pregnancy are generally curable with the appropriate risk-based therapies, experts say.
News
- Author:
- Neil Osterweil
Publish date: August 14, 2018
Risks for triple-negative breast cancer associated with pathogenic variants in five genes ranged from about 5.5-fold to nearly 17-fold.
News
- Author:
- Neil Osterweil
Publish date: August 14, 2018
Radiogenomic analysis showed that well-defined tumor margins and other features were associated with specific clinical presentations.
News
- Author:
- Neil Osterweil
Publish date: August 11, 2018
Having health insurance can mean the difference between life and death for US patients with follicular lymphoma (FL), according to research publish...
News
- Author:
- Neil Osterweil
Publish date: August 10, 2018
Chemotherapy halved the risk of disease progression and death for patients with low probability of 10-year overall survival.
News
- Author:
- Neil Osterweil
Publish date: August 10, 2018
Vismodegib was associated with a higher complete response rate than sonidegib in patients with locally advanced basal cell carcinoma.
News
- Author:
- Neil Osterweil
Publish date: August 9, 2018
Short alternating cycles of sunitinib with regorafenib failed to reach active drug levels in patients with heavily pretreated disease.
News
- Author:
- Neil Osterweil
Publish date: August 9, 2018
CHICAGO – A broad spectrum KIT inhibitor should be a part of post-imatinib therapy for GIST, data from a phase 1 study suggest.
News
- Author:
- Neil Osterweil
Publish date: August 8, 2018
CHICAGO – Combined with another investigational tyrosine kinase inhibitor, the compound showed activity against a broad range of resistance mutatio...
